Effects of calcium–vitamin D co-supplementation on metabolic profiles in vitamin D insufficient people with type 2 diabetes: a randomised controlled clinical trial
- 1.1k Downloads
This study was performed to assess the effects of vitamin D and calcium supplementation on the metabolic profiles of vitamin D insufficient persons with type 2 diabetes.
In a parallel designed randomised placebo-controlled clinical trial, a total of 118 non-smoker individuals with type 2 diabetes and insufficient 25-hydroxyvitamin D, aged >30 years, were recruited from the Isfahan Endocrine and Metabolism Research Centre. Participants were randomly assigned to four groups receiving: (1) 50,000 U/week vitamin D + calcium placebo; (2) 1,000 mg/day calcium + vitamin D placebo; (3) 50,000 U/week vitamin D + 1,000 mg/day calcium; or (4) vitamin D placebo + calcium placebo for 8 weeks. A study technician carried out the random allocations using a random numbers table. All investigators, participants and laboratory technicians were blinded to the random assignments. All participants provided 3 days of dietary records and 3 days of physical activity records throughout the intervention. Blood samples were taken to quantify glycaemic and lipid profiles at study baseline and after 8 weeks of intervention.
30 participants were randomised in each group. During the intervention, one participant from the calcium group and one from the vitamin D group were excluded because of personal problems. Calcium–vitamin D co-supplementation resulted in reduced serum insulin (changes from baseline: −14.8 ± 3.9 pmol/l, p = 0.01), HbA1c [−0.70 ± 0.19% (−8.0 ± 0.4 mmol/mol), p = 0.02], HOMA-IR (−0.46 ± 0.20, p = 0.001), LDL-cholesterol (−10.36 ± 0.10 mmol/l, p = 0.04) and total/HDL-cholesterol levels (−0.91 ± 0.16, p = 0.03) compared with other groups. We found a significant increase in QUICKI (0.025 ± 0.01, p = 0.004), HOMA of beta cell function (HOMA-B; 11.8 ± 12.17, p = 0.001) and HDL-cholesterol (0.46 ± 0.05 mmol/l, p = 0.03) in the calcium–vitamin D group compared with others.
Joint calcium and vitamin D supplementation might improve the glycaemic status and lipid profiles of vitamin D insufficient people with type 2 diabetes.
Trial registration: ClinicalTrials.gov NCT01662193
Funding: Clinical Research Council, Isfahan University of Medical Sciences, Isfahan, Iran
KeywordsCalcium Glycaemia Metabolic profiles Type 2 diabetes Vitamin D
Fasting plasma glucose
HOMA of beta cell function
Isfahan Endocrine and Metabolism Research Center
The authors would like to thank the Food Security Research Center of Isfahan University of Medical Sciences. This paper is based on an MSc thesis (190136) from Isfahan University of Medical Sciences. Marjan Tabesh was the author of the MSc thesis.
The study was funded by the Clinical Research Council, Isfahan University of Medical Sciences, Isfahan, Iran
Duality of interest
The authors declare that there is no duality of interest associated with this manuscript.
Marj. T contributed to conception, design, statistical analyses, data interpretation, and manuscript drafting for this study. Marj. T, Mary. T, LA and EF contributed to the data collection and manuscript drafting. All authors approved the final manuscript for submission. AE is the guarantor of this work.
- 3.Ganji V, Zhang X, Shaikh N, Tangpricha V (2011) Serum 25-hydroxyvitamin D concentrations are associated with prevalence of metabolic syndrome and various cardiometabolic risk factors in US children and adolescents based on assay-adjusted serum 25-hydroxyvitamin D data from NHANES 2001–2006. Am J Clin Nutr 94:225–233PubMedCrossRefGoogle Scholar
- 10.Mitri J, Dawson-Hughes B, Hu FB, Pittas AG (2011) Effects of vitamin D and calcium supplementation on pancreatic beta cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: the calcium and vitamin D for diabetes mellitus (CaDDM) randomized controlled trial. Am J Clin Nutr 94:486–494PubMedCentralPubMedCrossRefGoogle Scholar
- 16.Noda M, Mizoue T (2010) Relation between dietary calcium and vitamin D and risk of diabetes and cancer: a review and perspective. JCMD 1:55–60Google Scholar
- 27.Inomata S, Kadowaki S, Yamatani T, Fukase M, Fujita T (1986) Effect of 1 alpha (OH)-vitamin D3 on insulin secretion in diabetes mellitus. Bone Miner 1:187–192Google Scholar
- 32.Li K, Kaaks R, Linseisen J, Rohrmann S (2012) Associations of dietary calcium intake and calcium supplementation with myocardial infarction and stroke risk and overall cardiovascular mortality in the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition study (EPIC-Heidelberg). Heart 98:920–925PubMedCrossRefGoogle Scholar
- 35.Johnson JA, Grande JP, Roche PC, Kumar R (1994) Immuno histochemical localization of the 1,25(OH)2D3 receptor and calbindin D28k in human and rat pancreas. Am J Physiol 267:356–360Google Scholar
- 43.Jolma P, Kööbi P, Kalliovalkama J et al (2003) Increased calcium intake reduces plasma cholesterol and improves vasorelaxation in experimental renal failure. Am J Physiol Heart Circ Physiol 285:1882–1889Google Scholar
- 47.Gerst EM, Rabl W, Rosenbauer J et al (2008) Metabolic control as reflected by HbA1c in children, adolescents and young adults with type-1 diabetes mellitus: combined longitudinal analysis including 27,035 patients from 207 centers in Germany and Austria during the last decade. Eur J Pediatr 167:447–453CrossRefGoogle Scholar